BOSTER
antibody and ELISA experts

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Anti-Phospho-IL8 beta (S347) CXCR2 Antibody

Catalog Number: A00455S347

Overview

Product Name	Anti-Phospho-IL8 beta (S347) CXCR2 Antibody
Reactive Species	Human
Description	Boster Bio Anti-Phospho-IL8 beta (S347) CXCR2 Antibody catalog # A00455S347. Tested in WB, IHC, IF, ELISA applications. This antibody reacts with Human.
Application	ELISA, IF, IHC, WB
Clonality	Polyclonal
Formulation	Liquid in PBS containing 50% glycerol, 0.5% stabilizing protein and 0.02% sodium azide. *This antibody is supplied in a stabilized formulation. Compatibility with conjugation reactions depends on the chemistry of the conjugation method used. For conjugation methods that are not compatible with the stabilizing components present in this formulation, a carrier-free antibody format is required.
Storage Instructions	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.
Host	Rabbit
Uniprot ID	P25025

Technical Details

Immunogen	The antiserum was produced against synthesized peptide derived from human IL-8R beta/CDw128 beta around the phosphorylation site of Ser347. AA range:311-360
Isotype	IgG
Form	Liquid
Concentration	1 mg/ml
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Suggested Dilutions	WB 1:500-1:2000 IHC 1:100-1:300 IF 1:200-1:1000 ELISA 1:10000

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Anti-Phospho-IL8 beta (S347) CXCR2 Antibody (A00455S347) Images



Upregulation of the expression of CXCR2 protein in TG in orofacial itch. (A) Double immunohistochemistry of CXCR2 and DAPI at 6 h and day 1 after incision. (B) Statistical analysis of CXCR2 immunofluorescence density at 6 h and day 1 after incision (n = 3 mice and 8–9 sections for each group). (C) Representative Western blot of CXCR2 in TG with incision. (D) Statistical analysis of CXCR2 protein with incision (n = 3 mice for each group) (E) Double immunohistochemistry of CXCR2 and IB4 with CQ and histamine injection. (F) Mean number of CXCR2 neurons after CQ and histamine injection (n = 3 mice and 6–8 sections for each group). Scale bars, 50 um. One-way ANOVA followed by Dunnett's multiple comparisons test in (B,D,G,H) . * p



Effects of the CXCR2 Antagonist SB225002 on oroficial itch. (A) Double immunohistochemistry of CXCR2 and IB4 in the saline and SB225002 treatment groups. (B) Statistical analysis of the immunofluorescence density of CXCR2 in saline and SB225002 treatment (n = 3 mice and 11 sections for each group). (C) Representative Western blot of CXCR2 with saline and SB225002 after incision. (D) Statistical analysis of CXCR2 protein with saline or SB225002 after incision (n = 3 mice for each group). (E) Effects of SB225002 on scratch behaviors induced by incision (n = 10 mice for each group). (F) Effects of SB225002 on scratch behaviors induced by CQ and histamine (n = 8 mice for each group). Scale bars, 50 um. Unpaired t test in (B,D,F) and 2-way ANOVA in (E) . * p



DION microinjection and effects of CXCR2 shRNA on orofacial itch. (A) Schematic of DiI and shRNA virus microinjection into DION. (B) Double immunohistochemistry of CXCR2 and DiI in TG neurons (n = 3 mice and 10 sections). Arrows indicate DiI-labeled CXCR2 neurons. (C) The proportion of DiI-positive neurons in TG neurons (n = 3 mice and 10 sections for each group). (D) Examples of immunofuorescence images of CXCR2 and GFP treated with scramble and shRNA. (E) Statistical analysis of CXCR2 immunofluorescence density with scramble and shRNA (n = 3 mice and 9 sections for each group). (F) Representative Western blot of CXCR2 with scramble and shRNA. (G) Statistical analysis of CXCR2 protein in TG with scramble and shRNA (n = 3 mice for each group). (H) Effects of CXCR2 shRNA injection on incision-induced scratch behaviors (n = 5–6 mice for each group). (I) Effects of the CXCR2 shRNA virus on scratch behaviors induced by CQ and histamine (n = 6–7 mice for each group). Scale bars, 50 um. Unpaired t test in (E,G,I) and 2-way ANOVA in (H) . * p

Effects of the CXCR2 and PI3K/Akt signal pathway on orofacial itch. (A) Double immunohistochemistry of CXCR2

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com



and Akt in TG. Arrows indicate CXCR2 and Akt positive neurons. (B) Representative Western blot of p-Akt, Akt, and CXCR2 with saline and LY294002 after incision. (C) Statistical analysis of the p-Akt protein with saline and LY294002 after incision (n = 3 mice for each group). (D) Statistical analysis of Akt protein with saline and LY294002 after incision (n = 4 mice for each group). (E) Statistical analysis of the CXCR2 protein with saline and LY294002 after incision (n = 3 mice for each group). (F) Effects of LY294002 on incision-induced scratch behavior (n = 5 mice for each group). (G) Effects of LY294002 on incision-induced scratch behaviors (n = 7 mice for each group). Scale bars, 50 um. One-way ANOVA followed by Tukey's multiple comparisons test in (C,D,E) , 2-way ANOVA in (F) , and unpaired t test in (G) . * p

Submit a product review to Biocompare.com

Submit a review of this product to Biocompare.com to receive a $20 Amazon.com giftcard! Your reviews help your fellow scientists make the right decisions. Thank you for your contribution.

Anti-Phospho-IL8 beta (S347) CXCR2 Antibody

For Research Use Only. Not for use in diagnostic procedures.